Download Free Medical Cancer PowerPoint Presentation

Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Cancer powerpoint presentation

Tags : cancer medicine,cancer

Published on : Jun 23, 2021 | Views : 1730 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Cancer Medicines: Value in Context May 2019
Slide 2-

ppt slide no 2 content not found
Slide 3-

3 We have made remarkable progress in the fight against the more than 200 diseases we call cancer and current research holds enormous promise to address the great unmet need. Too many cancer patients face financial burdens, and these come from a variety of sources including treatment costs, non-medical costs, and insurance benefit design. The cost of cancer treatment comes from a range of sources including medicines, hospital and ED visits, diagnostics, and physician services. The oncology market is working to control spending on cancer medicines and overall treatment costs. Reforms are needed to accelerate the development path for cancer medicines and promote a delivery system that is increasingly patient-centered and value- based. Key Takeaways
Slide 4-

4 1. Advances in Cancer Treatment
Slide 5-

5 Increases in cancer survival are estimated to translate to the avoidance of nearly 2.6 million cancer deaths. Since Peaking in the Early 1990s, Cancer Death Rates Have Declined 27% 215 156 Cancer Death Rate (Number of Deaths Due to Cancer per 100,000) 1991 2016 Source: American Cancer Society, “Cancer Facts & Figures 2019,” https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. U.S. Death Rates from Cancer Decline Over Time -27%
Slide 6-

6 Since 1975, the chances that a cancer patient will live 5 years or more have increased by 41% across cancers.1 Five-Year Survival is Increasing for Many Types of Cancer 0% 20% 40% 60% 80% 100% Breast Cancer Prostate Cancer Colon/Rectum Lung/Bronchus 5-Year Survival Rates Among the Most Common Cancers, 1975-20141 1975 2014 73% of recent survival gains in cancer are attributable to treatment advances including new medicines.2 Sources: 1) American Cancer Society, “Cancer Facts & Figures 2019,” https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and- figures/2019/cancer-facts-and-figures-2019.pdf. 2) S. Seabury, “Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection,” Forumfor Health Economics and Policy 2016; 19(1): 141–156.
Slide 7-

7 The continued increase in survival rates is in large part attributable to earlier detection and better treatments.1 The Number of Cancer Survivors is Steadily Rising U.S Cancer Survivors Over Time (millions)1,2,3 26.1 21.7 16.9 9.8 3 1971 2001 2019 2029 (Projected) 2040 (Projected) Sources: 1) American Cancer Society, “Cancer Treatment and Survivorship Facts & Figures, 2016-2017,” http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-048074.pdf. 2) Centers for Disease Control and Prevention, “Cancer Survivors-United States, 2007,” 10 March 2011, http://www.cdc.gov/cancer/survivorship/what_cdc_is_doing/research/survivors_article.htm. 3) National Institutes of Health, National Cancer Institute, Office of Cancer Survivorship Statistics, https://cancercontrol.cancer.gov/ocs/statistics/statistics.html#ref1 (accessed May 2019).
Slide 8-

8 Engineered immune T-cells can recognize, zero in on and kill cancer cells. CAR-T Therapy Driving Breakthroughs for Cancer Patients
Slide 9-

9 Immunotherapy is Revolutionizing the Treatment of Many Advanced Cancers: Metastatic Melanoma “No recent cancer advance has been more transformative than immunotherapy.” - Dr. Julie M. Vose, former President of the American Society of Clinical Oncology3 Note: Data from KEYNOTE-001 pembrolizumab clinical study Sources: 1) ASCO, “PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma,” May 18, 2016, https://www.asco.org/about-asco/press- center/news-releases/pd-1-inhibitor-pembrolizumab-provides-long-term-survival; 2) The ASCO Post. “ASCO Names Advance of the Year, Highlights Major Top Research Trends.” February 10 2016. http://www.ascopost.com/issues/february-10-2016/asco-names-advance-of-the-year-highlights-major-top-research-trends/; 3)Southall, A. “Former President Jimmy Carter Says He is Free of Cancer.” http://www.nytimes.com/2015/12/07/us/jimmy-carter-cancer.html. Dec. 6, 2015.
Slide 10-

10 Among teenage girls, widespread use of the quadrivalent human papilloma virus (HPV) vaccine has driven down infection rates by nearly two-thirds. Cervical Cancer: Reduced Incidence of Cancer-Causing HPV Infections Source: Markowitz, L, et al. “Prevalence of HPV After Introduction of the Vaccination Program in the United States.” Pediatrics. March 2016. http://pediatrics.aappublications.org/content/early/2016/02/19/peds.2015-1968.
Slide 11-

11 A greater understanding of the molecular basis of disease has transformed what was once known collectively as “disease of the blood,” into multiple subtypes of leukemias and lymphomas, opening up new treatment approaches. Transformation in Cancer Diagnosis Has Led to More Precise Treatment “Disease of the Blood” Lymphoma Leukemia 60 YEARS AGO 50 YEARS AGO Aggressive Lymphoma Acute Leukemia Pre- leukemia Indolent Lymphoma 40 YEARS AGO Chronic Leukemia TODAY 5 year survival rates have grown to 70% There are nearly 340 medicines in development for blood cancers ~ 40 Unique Leukemia types identified ~ 50 Unique Lymphoma types identified Source: M Aspinal, former President Genzyme Genetics (http://www.comtecmed.com/biomarker/2014/Uploads/Editor/PDF/ppt/Edward%20Abrahams_Key%20Note%20Lecture.pdf)l; National Cancer Institute,; SEER Cancer Statistics Review, 1975-2011, http://seer.cancer.gov/csr/1975_2011 /, based on November 2013 SEER data submission, posted to the SEER web site, April 2014; PhRMA, Medicines in Development for Cancer, May 2018.
Slide 12-

12 Since the approval of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), survival rates have improved dramatically and patients are living close to normal life spans.1 Targeted Therapies Drive Survival Gains in Chronic Leukemias Imatinib—the first TKI—was approved in 2001 to treat CML. The transformative impact of this class of medicines had not been completely realized. After initial approval, continued research revealed that imatinib had a greater impact when initiated earlier in the progression of the disease. Further research also revealed that imatinib was effective in combating other types of cancer. Additional TKIs have since been approved for CML and offer alternatives to imatinib. 31% 89% Prior to Introduction of Imatinib After Introduction of Imatinib 5-Year Survival Rates for CML Patients Nearly Triple After Introduction of Imatinib2 Sources: 1) PhRMA, “A Decade of Innovation in Cancer: 2006‐2016,” http://phrma-docs.phrma.org/sites/default/files/pdf/decade-of-innovation-cancer.pdf, 2016; 2) BJ Druker, et al., “Five‐year follow‐up of patients receiving imatinib for chronic myeloid leukemia,” N Engl J Med. 2006; 355(23):2408‐17.
Slide 13-

13 Personalized medicines provide effective and efficient care by targeting the right medicine to the right patient. The Role of Personalized Medicines Is Rapidly Growing 11% 26% 15% 48% 2003 20% 10% 24% 46% Targeted Therapies 2013 Oncology Treatment Modalities in Top Pharmaceutical Markets, Share of Sales, 2003-2013 Targeted Cytotoxics Supportive Care Hormonals (Chemo) Source: IMS Institute for Healthcare Informatics, “Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report,” May 2014.
Slide 14-

14 Cancer Treatment Advances Result in Substantial Gains to Society 23 million years of life saved due to cancer treatment advances Between 1988 and 2000: $1.9 trillion value of improved cancer treatment to society based on improved productivity, extended life and other factors Source: DN Lakdawala , et al., “An economic evaluation of the war on cancer,” Journal of Health Economics. May 2010. 29(3):333-346.
Slide 15-

15 2. Innovation in the Cancer Medicine Pipeline
Slide 16-

16 Promise in the Pipeline: More than 1,100 Medicines in Development for Various Cancers “These are exciting times… the pace of discovery and application of new knowledge to patient care is rapidly accelerating.” — Dr. Jose Baselga, Physician-in-Chief, Memorial Sloan Kettering Cancer Center *Some medicines may be in more than one therapeutic category. Sources: PhRMA, Medicines in Development for Cancer, May 2018; American Association for Cancer Research. “Jose Baselga, MD, PhD” http://cancerprogressreport.org/2015/Pages/baselga.aspx . Bladder Brain Breast Colorectal Gastric Head and Neck Hematologic Malignancies Kidney Leukemia Liver Lung Lymphoma Multiple Myeloma Ovarian Pancreatic Prostate Sarcoma Skin Phase I Phase II Phase III Application Submitted Medicines and Vaccines in Development for Cancer by Tissue of Origin (Selected) – May 2018
Slide 17-

ppt slide no 17 content not found
Slide 18-

18 Researchers are using novel approaches to attack cancer at the molecular level. An average of 85% of drugs in the oncology pipeline, including 79% in the clinical research phase, have the potential to be first-in-class medicines. New Approaches to Treating Cancers Represent the Majority of Medicines in the Oncology Pipeline 84% 92% 88% 78% 80% 83% 71% 85% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Cancer, general Bladder cancer Blood cancers Breast cancer Colorectal cancer Lung cancer Melanoma Prostate cancer Percentage of Projects in Development that are Potentially Novel Approaches in Selected Cancer Areas, 2016 Source: Long, G. “The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” Analysis Group. June 2017.
Slide 19-

19 Biopharmaceutical Companies are Researching New Targeted Cancer Therapies Sources: Tufts Center for the Study of Drug Development (CSDD). Personalized medicine gains traction but still faces multiple challenges. Tufts CSDD Impact Rep. 2015.
Slide 20-

20 The cancer pipeline is ripe with innovative therapeutic options. Emerging combinations of medicines hold particular promise for controlling and killing cancer cells. Major Scientific Advances in Cancer Treatment Pipeline Give Patients Hope “We are in the midst of a sea change in how we are treating cancer. We’re really seeing the fruits of many years of research into what drives cancer and how it interacts with the immune system to defeat it and survive.” - Dr. Louis Weiner, director of the Georgetown Lombardi Comprehensive Cancer Center PARP inhibitors interrupt cancer’s hyperactive DNA repair systems, thus allowing tumors to be crippled and die. Oncolytic viral therapies zero in on cancer cells, replicate, and cause them to rupture. CRISPR/Cas9 gene editing allows researchers to manipulate cancer cell function. Sources: World Medical Innovation Forum: Cancer. “Disruptive Dozen 2016.” http://worldmedicalinnovation.org/wp-content/uploads/2016/04/Partners-FORUM-2016-BROCHURE-D12- Cancer-160422_0942-FREV1-WEB-X3-SM-SPREADS.pdf; McGinley, L. “The list of cancers that can be treated by immunotherapy keeps growing.” The Washington Post. https://www.washingtonpost.com/news/to-your-health/wp/2016/04/19/breakthrough-cancer-therapy-shows-growing-promise/; M. Eisenstein, “Top 40 Drugs in the Pipeline – 2016,” C&EN Supplement, September 2016, http://cen.acs.org/content/dam/cen/supplements/09435-cens-web.pdf (Accessed 14 March 2017). Immunotherapies help target and kill cancer cells by unleashing the immune system. (e.g. CAR-T)
Slide 21-

21 Developing a new cancer medicine is a complex process, fraught with setbacks, but these so called “failures” are not wasted efforts. Researchers learn from them to inform future study. Cancer Researchers Build on Knowledge Gained from Setbacks to Inform Advances MELANOMA 96 unsuccessful attempts 7 new medicines BRAIN CANCER 75 unsuccessful attempts 3 new medicines LUNG CANCER 167 unsuccessful attempts 10 new medicines *Setbacks and advances from 1998 to 2014 Source: PhRMA, “Researching Cancer Medicines: Setbacks and Stepping Stones,” http://www.phrma.org/sites/default/files/pdf/2014-cancer-setbacks-report.pdf, 2014.
Slide 22-

22 Lung-MAP (Lung Cancer Master Protocol) matches patients to specific investigational medicines based on genomic screening. Shared infrastructure accelerates drug development and increases efficiency. Lung-MAP: Innovative Clinical Trial Takes New Approach to Cancer Drug Development Lung-MAP is a unique public-private partnership between: Patient and disease advocacy groups Biopharmaceutical companies National Cancer Institute Foundation for the National Institutes of Health HOW IT WORKS: Patients undergo genomic profiling to identify mutations that may cause non-small cell lung cancer Patients are directed to a treatment arm based on their genomic profile Patients receive highly targeted therapies and researchers collect data to advance the study of new medicines Source: Lung Cancer Master Protocol, http://www.lung-map.org/ (accessed May 2019). THE PARTNERS:
Slide 23-

23 3. Cancer Patient Spending and Financial Burden
Slide 24-

24 Multiple Factors Contribute to the Financial Burden Faced by Cancer Patients Source: Financial Hardship Associated with Cancer. CancerCare, 2017. 23% 38% 42% 48% 49% Gasoline Food (Groceries or Dining Out) Over-the-Counter Medicines Special Clothing and/or Wigs Car Repairs Top Patient Financial Concerns 36% 37% 39% 43% 53% Diagnostic Tests or Scans Prescription Medicines Physician Office Visits Outpatient Treatments (Incl. Radiation) Surgery Non-Medical Medical
Slide 25-

25 A Cancer Diagnosis Impacts Productivity and Employment for Patients and Caregivers Sources: Financial Hardship Associated with Cancer. CancerCare, 2017.; Yabroff et al. Financial Hardship Associated with Cancer in the United States: Findings from a Population- Based Sample of Adult Cancer Survivors (2016), deMoor et al. 2016. Employment implications of informal cancer caregiving; Yabroff & Kim. 2009. Time costs associated with informal caregiving for cancer survivors. Patients Caregivers 67% of patients who were employed full-time when diagnosed either stopped working or reduced their work hours More than 25% of caregivers made extended employment changes
Slide 26-

26 At 6 months post-diagnosis, 60-70% of out-of-pocket costs are driven by physician and facility care for commercially insured patients with breast, lung and colorectal cancer on average. Out-of-Pocket Costs Are Not Driven by Cancer Medicines 41% Professional Services 4% Breast Cancer Patient Out-of-pocket Costs At 6 Months Following Diagnosis Cancer Related Drugs Source: G. Dieguez, et al, Milliman Research Report: “A Multi-Year Look at the Cost Burden of Cancer Care,” 11 April 2017 Hospital Inpatient Radiation Therapy
Slide 27-

*There are no generic drugs available in this class. All products are single-source. 27 Source: Avalere Health PlanScape®, a proprietary analysis of exchange plan features, April 2016. This analysis is based on data collected by Managed Markets Insight & Technology, LLC. Some plans place treatments for certain high-cost conditions on the highest drug formulary cost sharing tier. Benefit Design Hinders Access to Cancer Medicines in Some New Classes 50% 23% Antiangiogenics* Molecular Target Inhibitors* Percentage of Silver Plans Placing All Drugs per Class on Specialty Tier, 2016
Slide 28-

28 10% 11% 14% 32% 41% 49% <$10 $10-$50 $50-$100 $100-$500 $500-$2000 >$2000 Oral Oncolytic Abandonment Rate by Patient Out-of-Pocket Amount Patients with highest co-pay were 5 times more likely to abandon treatment than the lowest co-pay group High Cost Sharing Leads to Abandonment or Delays in Cancer Treatment Source: Doshi JA, Li P, Huo H, Pettit AR, Armstrong KA. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. Journal of Clinical Oncology. 2017 Dec 20:JCO-2017. Available online at: http://ascopubs.org/doi/pdf/10.1200/JCO.2017.74.5091
Slide 29-

29 4. Cancer Costs in Context
Slide 30-

* 2018 CMS total National Health Expenditures is a projection ** Cancer drug invoice spending and does not include discounts Sources: 1) IQVIA Institute. Medicine Use and Spending in the U.S. A Review of 2018 and Outlook to 2023. https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the -us-a-review- of-2018-and-outlook-to-2023. Published May 2019. 2) Centers for Medicare & Medicaid Services (CMS) data. National health expenditures (NHE) table 2 Amounts and Annual Percent Change30 by Type of Expenditure. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected.html. Accessed April 2019. Cancer Medicines as a Portion of Total U.S. Health Care Spending, 2018* Cancer Medicines $58.4 Billion1** $3.65 Trillion2* Remaining Health Care Spending Spending on Cancer Medicines Represents Less than 2% of Overall Health Care Spending
Slide 31-

31 34% 11% 8% 3% 21% 5% 18% Cancer Drugs Medicare, Actively Treated Cancer Population, 2014 Hospital Inpatient Other Out Pt Services Cancer Surgeries Professional Services Radiology Cancer Drugs Radiation Oncology Cancer Medicines Represent About 20% of Cancer Spending 20% 13% 10% 4% 28% 4% 20% Cancer Drugs Commercially Insured, Actively Treated Cancer Population, 2014 Source: K. Fitch, et al. Milliman, “Cost Drivers of Cancer Care: A Retrospective Analysis of Medicare and Commercially Insured Population Claim Data 2004-2014,” April 2016, http://www.milliman.com/uploadedFiles/insight/2016/trends-in-cancer-care.pdf.
Slide 32-

32 Overall Drug Spending Growth Expected to be Moderate as Cancer Progress Continues 0 200 300 400 500 Projected Net Total Drug Spending Growth = 3-6% per year 100 $56.7 Billion $344 Billion Projected Cancer Drug Spending as a Portion of Total Drug Spending, US$ Billions Sources: IQVIA Institute. Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications. Published May 2019 and IQVIA Institute. “Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023” Published May 2019.
Slide 33-

33 The volume-weighted Average Sales Price (ASP) for cancer drugs administered through Medicare Part B has been growing in line with medical inflation. Weighted ASP (Oncology Drugs vs. All Other Drugs) vs Consumer Price Index – Medical (CPI-M) Prices of Cancer Medicines in Medicare Part B Growing Slowly Source: The Moran Company. Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2006-2017. December 2017.
Slide 34-

Cancer Treatments Face Growing Competition from Generics and Biosimilars 4.4 11.3 2.1 2.2 4.2 2019 2020 2021 2022 2023 $25.5 Billion *Pre-Expiry spending is the actual and estimated spending in the 12 months prior to loss of exclusivity (LOE) and is shown for developed markets only. Estimates are based on patent expiry dates or expected generic/biosimilar availability, and historic analogues where available. Biologics and small molecules are modeled separately. Biologic brand sales at risk are based on any non-original biologic competitor, regardless of approval type. 34 Sources: IQVIA Market Prognosis, National Sales Perspectives, QuintilesIMS Institute, May 2019. Includes small and large molecules. Global Oncology Sales at Risk of Reduction Due to Estimated Loss of Exclusivity (Billions of US Dollars)*
Slide 35-

35 Market Drives Rapid Switch to Generic Medicines: Example - Injectable Cancer Medicine Docetaxel Sources: Bates White Economic Consulting, “Oncology Product Sales and Patent Expiration: A Policy Brief,” May 2017. LOSS OF EXCLUSIVITY
Slide 36-

36 Market Drives Rapid Switch to Generic Medicines: Example - Injectable Cancer Medicine Gemcitabine Sources: Bates White Economic Consulting, “Oncology Product Sales and Patent Expiration: A Policy Brief,” May 2017. LOSS OF EXCLUSIVITY
Slide 37-

37 Advanced melanoma patients who were adherent to immunotherapy experienced 10% lower health care costs. Better Use of Cancer Medicines Can Reduce Health Care Costs All-Cause Costs Melanoma-Related Costs Source: Gupte-Singh K, Lin J, Lingohr-Smith M, Menges BL, Rao S. Adherence to cancer therapies and the impact on healthcare costs among patients with advanced melanoma in the USA. Proceedings of the 22nd Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research; 2017 May; Boston, MA. Abstract available at: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/70971?pdfid=49558. Difference in total healthcare costs by adherence status for advanced melanoma patients $51,991 $48,263 $41,830 $37,549 Low Adherence High Adherence
Slide 38-

38 5. Evolving Cancer Market Dynamics
Slide 39-

39 82% 76% Office Administered Oral Health Plans Make Extensive Use of Prior Authorization in Oncology Source: Health Strategies Group. Cost Containment in the Market for Branded Pharmaceuticals. August 2018. https://www.healthstrategies.com/executive-briefs. Health Plans’ Use of Prior Authorization in Oncology
Slide 40-

40 59% 35% 31% Contracting for preferred first-line therapies Using clinical pathways to determine treatment regimens Utilizing one or more value frameworks* in determining reimbursement Current and Anticipated Payer Measures to Manage Oncology Costs (Q1 2017) Health Plans Deploy a Range of Tools to Manage Cancer Drug Spending *Value Frameworks: NCCN Evidence Blocks, ASCO Value Framework, etc. Source: Zitter Health Insights , Managed Care Oncology Index, 2016.
Slide 41-

41 Non-small cell lung cancer patients treated according to a clinical pathway incurred lower drug and total costs. Plans and Providers Rapidly Adopting Clinical Pathways -22% -28% -28% -23% -18% 5% OVERALL Chemotherapy, biologics Radiology Radiation Therapy Non-chemo infusions, transfusions Diagnostics 12-Month Savings with Lung Cancer Clinical Pathway* Source: DM Jackman et al “Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer, “ Journal of Oncology Practice, April 2017, http://ascopubs.org/doi/abs/10.1200/JOP.2017.021741 *Clinical pathways are care plans that provide specific guidance on the sequencing of care steps and the timeline of interventions. They often consider evidence on the benefits and harms of alternati care options and take the cost therapy into account.
Slide 42-

42 Early results from oncology medical homes, bundled payment and specialty Accountable Care Organizations (ACOs) show potential for reducing total cancer costs. Plans Realize Savings via New Payment Models Patient-centered medical homes Pilot reduced total costs 35% annually Episode- or bundled payment Pilot reduced total costs of care 34% Specialty ACOs Reduce drug spending 5%, total spending 2% + Source: S. Shah, G. Reh, “Value-Based Payment Models in Oncology: Will They Help or Hinder Patient Access to New Treatments?” AJMC, 18 April 2017, http://www.ajmc.com/journals/evidence-based-oncology/2017/april-2017/value-based-payment-models-in-oncology-will-they-help-or-hinder-patient-access-to-new-treatments "Notably, all those interviewed suggested that the use of clinical pathways was a driver of financial savings, either through reduced drug spending or indirectly through more appropriate patient treatment.” - Sonal Shah, PharmD, and Greg Reh, American Journal of Managed Care
Slide 43-

43 Nearly 200 oncology practices are participating in the Oncology Care Model (OCM) to improve quality an reduce the cost of cancer care in Medicare Part B. OCM* Practice Results – Performance Period One Market Shift to New Payment Models: CMS’ Oncology Care Model 100% 60% 25% Implementing Guidelines-Based Care Achieving significant savings Achieving a performance-based payment *The Oncology Care Model (OCM) aims to provide higher quality, more highly coordinated oncology care at the same or lower cost to Medicare. Under OCM, physician practices have entered into payment arrangements that include financial and performance accountability for episodes of care surrounding chemotherapy administration to cancer patients. The practices participating in OCM have committed to providing enhanced services to Medicare beneficiaries such as care coordination, navigation, and national treatment guidelines for care. CMS is also partnering with commercial payers in the model. Source: Journal of Clinical Pathways. “Early Data Show Positive Trend in OCM Cost Savings” March 27, 2018.
Slide 44-

44 Source: IQVIA. 2018 and Beyond: Outlook and Turning Points. March 2018. Available online at: https://www.iqvia.com/institute/reports/2018-and-beyond-outlook-and-turning-points Shared risk or outcomes-based contracts (OBCs) between health insurers and manufacturers are becoming more common across diseases, including oncology. Manufacturers and Insurers Pursuing Outcomes-Based Contracts in Oncology 20 10 0 30 40 50 60 70 2013-2017 2018-2022 Number of Private Sector Risk-Sharing Contracts Publicly Announced More than 40% of the 65 outcomes-based contracts projected between 2018-2022 are expected to be in oncology.
Slide 45-

45 Site of Care Shifts Drive Higher Cancer Costs Source: Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA oncology. 2018 Apr 1;4(4):580-1. Available online at: https://jamanetwork.com/journals/jamaoncology/fullarticle/2673075. 92% 6% 2% 55% 43% 2% The rate of commercially insured patients receiving infused chemotherapy in hospitals increased from 6% of transfusions in 2004 to 43% in 2014. 2004 2014 Physician Office Hospital Outpatient Department Other
Slide 46-

46 Site of Care Shifts Drive Higher Cancer Costs Source: Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA oncology. 2018 Apr 1;4(4):580-1. Available online at: https://jamanetwork.com/journals/jamaoncology/fullarticle/2673075. $1,466 $3,799 $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 Physician Office Hospital Outpatient Department Commercial spending on chemotherapy infusions and oncology 6-month treatment episodes are twice as high in the hospital outpatient department compared to the physician office setting. Average Drug-Level Spending on Infused Chemotherapy (2004-2014) $4,000
Slide 47-

47 Hospital Consolidation Associated with Increases in Cancer Spending Source: Conti RM, Landrum MB, and Jacobson M. The impact of provider consolidation on outpatient prescription drug-based cancer care spending. 2016. Per Person Price of Treatment Per-Person Annual Spending Spending increases associated with just a 1% increase in the proportion of medical providers affiliated with hospitals and/or health systems. 34% 23%
Slide 48-

48 340B Creates Incentives to Shift Delivery of Physician- Administered Cancer Medicines to More Expensive Hospital Settings 11% 13% 15% 19% 24% 28% 32% 33% 35% 38% 17% 18% 18% 17% 18% 19% 19% 18% 17% 16% 73% 70% 67% 64% 58% 53% 50% 49% 48% 46% Site of Care for Breast Cancer Drug Therapies Reimbursed in Medicare Part B 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 340B Hospitals Non-340B Hospitals Physician Offices Source: Berkeley Research Group, Site of Care Shift for Physician-Administered Drug Therapies, March 2019.
Slide 49-

49 6. US System in Context
Slide 50-

50 Other developed countries use centralized government price setting and coverage decisions to manage drug spending, resulting in significantly slower access to medicines than in the US. US Patients Have Access to Cancer Medicines on Average Two Years Earlier Than Patients in Other Developed Countries 22 15 21 17 10 17 10 15 10 13 10 7 10 4 0 10 20 30 40 Germany France UK Italy Spain Australia Taiwan Months Average Time Delay Compared to the US in the Approval and Reimbursement of Oncology Medicines from 2010 to 2014 Delay Between US Approval and Country-Specific Approval Delay Between Country Approval and Reimbursement Source: PhRMA analysis of IMS Consulting Group “Patient Access to Innovative Oncology Medicines Across Developed Markets”. June 2016
Slide 51-

51 77 46 44 30 18 16 16 9 6 6 0 10 20 30 40 50 60 70 Availability of Oncology Medicines within One Year of Global Launch, 2011-2018 80 US Germany UK Canada France Italy Japan Australia Spain South Korea More Cancer Medicines are Available to US Patients Source: PhRMA analysis of IQVIA Analytics Link and FDA, European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) data on oncology new active substances first launched globally from 2011 to 2018, June 2019.
Slide 52-

52 Cancer death rates are lower in the US where patients have access to cancer medicines about 2 years earlier than in other developed countries US Patients Have Better Outcomes in Cancer 115.2 119.7 120.5 122.8 Age-Standardized Cancer Death Rates, 2013* 128.9 France Germany UK Source: PhRMA analysis of WHO Mortality Database, May 2019. Note: 2013 data was used because some countries lack newer data. USA Italy *2013 is the latest year for which data are available for all listed countries. Deaths per 100,000
Slide 53-

53 Health technology assessment (HTA) recommendations across countries show little consistency, highlighting the effect of cultural factors on HTA design and implementation, and that a “one-size-fits-all” approach is not realistic in determining access to needed medicines. In Other Countries, Governments Restrict Access to Cancer Medicines Source: Data provided by Avalere Health (citation forthcoming). Outcome of Health Technology Assessments for Cancer Treatments (2013 - 2017) 7 15 55 70 70 20 17 22 16 6 8 Canada (CADTH/pCODR) Germany (IQWiG/G- France (HAS) BA) United Kingdom (NICE) Recommended Recommended with Restriction Not Recommended In the U.K. only 7 government assessments recommended without restrictions. Outcomes were classified as “Recommended with Restrictions” if there were limitations that may impact access.
Slide 54-

54 Americans diagnosed late-stage non-small cell lung cancer gained an estimated 201,700 life years from 2006 to 2017 due to innovative medicines being made available with little to no delay after regulatory approval. Patients would have lost half of these survival gains if the United States had adopted HTA frameworks like those used by foreign governments to determine access to care. Lung Cancer Patients Experience Better Survival Under the Market Access Policies in the United States Source; IHS Markit. Comparing Health Outcome Differences Due to Drug Access: A Model in Non-Small Cell Lung Cancer. December 2018. https://ihsmarkit.com/research- analysis/population-health-outcomes-american-patients.html
Slide 55-

55 7. Solutions For Advancing Value in Cancer Care
Slide 56-

56 Advancing the Path for Development of New Cancer Medicines Integrating Patient Perspective Advances in regulatory science are creating efficiencies and enhancing the tools needed to drive innovative cancer drug discovery, development and approval. Solutions For Accelerating Cancer Progress Incorporate patient input & increase patient engagement. Enable use of both safety & efﬁcacy data in regulatory decision making. Enhance use of adaptive & other flexible study designs Increase acceptance of novel outcome measures Accelerating Qualification & Use of Biomarkers Advancing Use of Real-World Evidence Increasing Acceptance of Novel Clinical Trial Designs
Slide 57-

57 Biopharmaceutical Companies Advancing Patient-Centered Solutions for Better Value Expand Value- Based Contracts Strengthen Decision Support Tools Increase Availability of Evidence on Value Develop Quality Measures Improve Use of Medicines SOLUTIONS FOR BETTER CANCER CARE
Slide 58-

58 Value Based Contracts Value Frameworks Quality Measures Enabling the Cancer Drug Market’s Move to Value Expand value-based contracts by modernizing outdated regulations. “[R]egulatory reforms can address these concerns and encourage more robust competition within the drug market.” - Scott Gottlieb & Kavita Patel Develop better data and tools to support informed decision-making by patients, physicians and payers. “[E]merging approaches for assessing drug value are welcome….The frameworks will require refinement, however, before they're ready to be broadly applied.” - Peter Neumann & Joshua Cohen Close gaps in clinical and patient-focused quality measures. “All phases of the cancer care continuum…need new measures.” - National Academy of Medicine Sources: S Gottlieb, K. Patel, “A Fair Plan for Fairer Drug Prices,” Health Affairs, 11 July 2016; Institute of Medicine, “Delivering High-Quality Cancer Care: P. Neumann, J. Cohen, “Measuring the Value of Prescription Drugs,” NEJM, December 2015; Institute of Medicine, “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,” 2013.